Also found in: Dictionary, Financial, Encyclopedia.


A gene on chromosome 21q21.3 that encodes a cell surface receptor and transmembrane precursor protein which is cleaved by secretases to form various peptides.

Molecular pathology
APP mutations are implicated in autosomal dominant Alzheimer’s disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy).


Amyloid beta peptide. It is the toxic peptide that causes damage to neurons in patients having Alzheimer disease.
References in periodicals archive ?
The new study also showed that neurons from HspB1-deficient mice were more sensitive to the toxic ravages of Abeta.
We knew that Type 2 diabetes could increase the risk for Alzheimer's disease, but we were not sure how that risk was caused or whether that diabetes risk would impact Abeta levels in the brain.
After one year, however, these mice have Abeta plaques, as well as a decrease in spine density due to the effect of Abeta, which is known to be neurotoxic.
About CogRx's Small Molecule Soluble Abeta Receptor Antagonist Program CogRx has discovered small molecule drug candidates that can dramatically reduce toxic Abeta oligomer binding to receptor proteins on the brain cells at synapses by over 90%.
Investigators collected preliminary evidence of treatment efficacy including cognitive and global measures and secondary outcomes including activities of daily living, behavioral disturbances, pharmacokinetic parameters and a number of Alzheimer's disease biomarkers including Abeta peptide levels.
It is possible the result may point to PBT2 targeting soluble species of Abeta including toxic oligomers rather than plaques.
In a previous study, Holtzman had shown that synaptic activity triggers Abeta release, suggesting that the sleep-deprived mice in the current study churned out more Abeta because their brains were revved up longer than usual.
ACC-001 (active Abeta immunotherapeutic conjugate) is currently in Phase 1 clinical trials.
Caffeine, at levels comparable to 5 cups of coffee daily, reduces levels of the proteins that go into manufacture of Abeta, and lowers levels of Abeta itself in blood and brain tissue.
The Phase 1 trials for ACC-001 (active Abeta immunotherapeutic conjugate) are progressing as planned.
19), (44) It slows cell death following exposure to the dangerous "Alzheimer's protein" called Abeta (amyloid beta), and other oxidant stressors.